Market closed

Pacira BioSciences/$PCRX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Pacira BioSciences

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Ticker

$PCRX
Sector
Health Care
Trading on
NASDAQ

Industry

Pharmaceuticals
Headquarters
Tampa, United States

Employees

712
Website
www.pacira.com

PCRX Metrics

BasicAdvanced
$976M
-
-$1.96
0.82
-

$976M

0.82

$34.01

$11.16

851K

2.252

1.811

57.868

85.971

6.68%

4.17%

-11.48%

1.408

1.3

3.15

5.056

4.40%

-2,447.09%

10.63%

13.03%

What the Analysts think about PCRX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Pacira BioSciences stock.

PCRX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

PCRX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

PCRX News

AllArticlesVideos
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc.(PCRX) Shareholders

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc.(PCRX) Shareholders

Accesswire·45 minutes ago
Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PCRX

Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PCRX

Accesswire·6 hours ago
Pacira BioSciences, Inc. Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm

Pacira BioSciences, Inc. Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm

Accesswire·7 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PCRX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Pacira BioSciences stock?

Pacira BioSciences (PCRX) has a market cap of $976M as of January 15, 2025.

What is the P/E ratio for Pacira BioSciences stock?

The price to earnings (P/E) ratio for Pacira BioSciences (PCRX) stock is 0 as of January 15, 2025.

Does Pacira BioSciences stock pay dividends?

No, Pacira BioSciences (PCRX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Pacira BioSciences dividend payment date?

Pacira BioSciences (PCRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Pacira BioSciences?

Pacira BioSciences (PCRX) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.